KHK7580

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperparathyroidism

Conditions

Hyperparathyroidism

Trial Timeline

Aug 1, 2013 → Mar 1, 2014

NCT ID

NCT01935856

About KHK7580

KHK7580 is a phase 1/2 stage product being developed by Kyowa Kirin for Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT01935856. Target conditions include Hyperparathyroidism.

What happened to similar drugs?

13 of 20 similar drugs in Hyperparathyroidism were approved

Approved (13) Terminated (2) Active (7)

✅Cinacalcet HClKyowa KirinApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

✅DenosumabAmgenApproved

✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03280264	Phase 3	Completed	Aug 30, 2017	Apr 9, 2019	Parathyroid Carcinoma
NCT02549417	Phase 3	Completed	Sep 29, 2015	Dec 22, 2016	Secondary Hyperparathyroidism
NCT02549404	Phase 3	Completed	Sep 28, 2015	Dec 28, 2016	Secondary Hyperparathyroidism
NCT02143271	Phase 1	Completed	May 1, 2014	Dec 1, 2014	Secondary Hyperparathyroidism
NCT01935856	Phase 1/2	Completed	Aug 1, 2013	Mar 1, 2014	Hyperparathyroidism

Competing Products

20 competing products in Hyperparathyroidism

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Alendronate 70mg weekly	Merck	Approved	35
Etelcalcetide	Amgen	Phase 3	40
Cinacalcet + Placebo	Amgen	Phase 2	35
Cinacalcet + Placebo	Amgen	Phase 3	40
Etelcalcetide + Placebo	Amgen	Phase 1	29
Sensipar (Cinacalcet HCl)	Amgen	Phase 2	35
AMG 073 + Placebo	Amgen	Phase 3	40
cinacalcet	Amgen	Phase 3	40